Gemini xl pet ct scanner

Manufactured by Philips

The Gemini XL PET/CT scanner is a diagnostic imaging device that combines positron emission tomography (PET) and computed tomography (CT) technologies. The core function of this system is to acquire high-quality imaging data that can be used for various medical applications, such as oncology, cardiology, and neurology.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

GEMINI PET/CT scanner PET/CT scanner Gemini XL CT scanners

2 protocols using gemini xl pet ct scanner

Quantifying Breast Cancer Response to Neoadjuvant Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

Before 18FDG-PET/CT imaging, patients fasted for 6 hours and blood glucose level had to be less than 7 mmol/L. ¹⁸FDG (5 MBq/kg) was administered and imaging (from mid-thigh level to the base of the skull with the arms raised) started almost 60 minutes later. The Gemini XL PET/CT scanner (Philips Medical systems) was used. CT data was acquired first (120 kV; 100 mAs; no contrast-enhancement). PET emission data was acquired in a 3-dimensional mode, with 2 min per bed position. The attenuation-corrected images were normalized for injected dose and body weight, and subsequently converted into Standardized Uptake Values (SUV), defined as: [tracer concentration (kBq/mL)] / [injected activity (kBq)/patient body weight (g)].
A 3D region of interest (3D-ROI) was drawn around the primary tumor only. When present, lymph nodes were not encompassing within the volume. Indeed, in a previous study [10 (link)], we observed that SUV value measured in axillary lymph nodes in addition to the measure within the primary tumor was not of added value to predict response to neoadjuvant chemotherapy in luminal breast cancer.
The change in SUV_max (maximum SUV value within the ROI) after two cycles of chemotherapy was expressed as ΔSUV_max (%) = 100 × (2^nd cycle SUV_max - baseline SUV_max)/baseline SUV_max.

de Cremoux P., Biard L., Poirot B., Bertheau P., Teixeira L., Lehmann-Che J., Bouhidel F.A., Merlet P., Espié M., Resche-Rigon M., Sotiriou C, & Groheux D. (2018). 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients. Oncotarget, 9(23), 16343-16353.

+ Open protocol

+ Expand

PET/CT Imaging for Breast Cancer Neoadjuvant Chemotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patients fasted for 6 h, and blood glucose level had to be less than 7 mmol/L. 18 F-FDG (5 MBq/kg) was administered, and imaging started almost 60 min later. A Gemini XL PET/CT scanner (Philips) was used. CT data were acquired first (120 kV; 100 mAs; no contrast enhancement). PET emission data were acquired for 2 min per bed position. SUV was defined as [tracer concentration (kBq/mL)]/[injected activity (kBq)/patient body weight (g)].
A 3-dimensional region of interest was drawn around the primary tumor and, when present, around axillary lymph nodes. The percentage DSUV max within the region of interest after 2 cycles of chemotherapy was calculated as 100 • (second-cycle SUV max 2 baseline SUV max )/baseline SUV max .
Pathology Assessment and Event-Free Survival pCR was defined as no evidence of residual invasive cancer in breast tissues or lymph nodes (2) . Absence of carcinoma in situ was not mandatory.
During neoadjuvant chemotherapy, the patients underwent clinical examination every 2 cycles. After surgery, the patients made follow-up visits every 4 mo for 2 y and then twice yearly. Events included local, regional, or distant recurrence or death. Event-free survival (EFS) was defined as the time between PET 1 (or the date of surgery if considering the impact of pathologic response on EFS) and the date of the first event or of the last follow-up.

Groheux D., Biard L., Giacchetti S., Teixeira L., Hindié E., Cuvier C., Vercellino L., Merlet P., de Roquancourt A., de Cremoux P., Resche-Rigon M, & Espié M. (2016). ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 57(4).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!